| |
|
|
|
Xtalks, online
2023 -7-12
Marketing and commercialization are not individual functions, but rather a cross-functional process. Everyone plays an important part to 1) collectively identify an unmet need; 2) design and develop new treatment approaches that advance the standard of care; and 3) drive awareness of the clinical insights that prove how, why and whom a better treatment approach can benefit.
Three resources that are too often squandered: time, insight and integration.
Time – As much as half the time allocated to a new drug’s patent life is spent in the discovery and development phase. Drug commercialization is seen as a late-stage activity that gets stage gated to clinical milestones. Companies too often hedge their bets and delay meaningful investment to prepare markets for their new science until they have greater certainty that the science actually works or that there is a regulatory likelihood of approval. Time is currency. And too often it is squandered with a “wait and see” mentality versus a prospective plan to leverage it to its fullest.
NODATA
Join this webinar to explore the featured speaker’s new drug commercialization perspective of these three things that imperil a successful launch. Discover the significance of time, insight, and integration in successful drug commercialization and how they contribute to market success.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Kipp Kreutzberg, Vice President of Sales and Marketing, Syneos One, Full Service Commercial at Syneos Health Raymond A. Huml, MS, DVM, RAC, Vice President of Medical and Scientific Strategy, Head of the Rare Disease Consortium and co-founder and Executive Sponsor of the Persons with Disabilities Employee Resource Group, Syneos Health Christopher M. Cashman, Independent Senior Executive Biopharma Drug Development/Commercialization
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -7-12
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|